Table 1.
Clinical characteristics and prevalence of germline mutations.
| Patients With P/LP germline variants | Patients without P/LP germline variants | Prevalence of P/LP germline variants | |
|---|---|---|---|
| Number of patients(N) | 106 | 1688 | 5.91% |
| Age at diagnosis—yrs | p = 0.28a | ||
| Mean ± SD | 58.36 ± 11.51 | 59.97 ± 11.54 | |
| Median (range) | 60.5(29–82) | 60(16–94) | |
| NA(N) | 2 | 77 | |
| Gender—N (%) | p = 0.56b | ||
| Female | 42(39.6) | 725(43.0) | 5.48% |
| Male | 64(60.4) | 961(57.0) | 6.24% |
| NA | 0 | 2 | |
| Histologic diagnosis—N (%) | p = 0.50b | ||
| LUAD | 75(70.7) | 1148(68.0) | 6.13% |
| LUSC | 10(9.4) | 160(9.4) | 5.88% |
| SCLC | 3(2.8) | 41(2.4) | 6.82% |
| Other type | 5(4.7) | 39(2.3) | 11.36% |
| NSCLC-NOS | 13(12.2) | 300(17.7) | |
| Stage at diagnosisc-N (%) | p = 0.75b | ||
| I | 1 (0.9) | 37 (2.2) | 2.63% |
| II | 3 (2.8) | 47 (2.8) | 6.00% |
| III | 8 (7.5) | 153 (9.1) | 4.97% |
| IV | 76 (71.7) | 1034 (61.2) | 6.85% |
| NA | 18(17.0) | 417 (24.7) |
P/LP pathogenic/likely pathogenic, NA not available, LUAD lung adenocarcinoma, LUSC lung squamous carcinoma, SCLC small cell lung cancer, NOS not otherwise specified; Other histology type included: large cell neuroendocrine carcinoma, adenosquamous carcinoma, sarcomatoid carcinoma, pleomorphic carcinoma, poorly differentiated carcinoma, mucoepidermoid carcinoma, lymphoepithelioid carcinoma, etc.
aP value is calculated with Mann–Whitney test.
bP value is calculated with Chi-square test or Fisher’s exact test.
cThe clinical stage was based on 8th AJCC non-small cell lung cancer stage edition.